We have investigated the effects of a low-dose
aspirin regimen (120 mg orally, then 20 mg twice daily) on the in vivo synthesis of
prostacyclin,
thromboxane and
prostaglandin E in man by measurement of their urinary metabolites (PGI2-M, TxB2-M, PGE-M) using gas chromatography-mass spectrometry. A comparison was made between the selectivity of low-dose
aspirin for
thromboxane vs
prostacyclin synthesis in patients with
atherosclerosis, age-matched controls without
vascular disease, and young healthy volunteers. After one week of treatment,
aspirin reduced TxB2-M synthesis to a similar extent in the three groups (mean declines of 86, 84 and 78% respectively), while there was an unexpected difference in effect on
PGI2-M, with only a 27% fall in the young volunteers but 53% and 54% declines in the patients with
vascular disease and their age-matched controls. Serum TxB2 was reduced greater than 98% in all groups while
PGE-M excretion was unchanged. These results indicate that bioselectivity for inhibition of Tx synthesis by
aspirin is more difficult to achieve in older subjects than in the young volunteers previously studied and that very low, frequent dosing, or a
sustained-release preparation of
aspirin would be needed to achieve bioselectivity for Tx inhibition in patients with
vascular disease.